Table 2. Diagnostic Accuracy of APRI for the Prediction of Significant Fibrosis in Various Studies.
| Author,Year | Cutoff | Sensitivity | Specificity | PPV | NPV | AUROC(95%CI) |
| Sebastiani, 2011 | 1.5 | 36% | 98% | 96% | 53% | 0.64(0.58–0.70) |
| Seto, 2011 | 0.5 | 89% | 41% | 42% | 89% | 0.71(0.63–0.80) |
| 1.5 | 29% | 88% | 55% | 72% | ||
| Bonnard, 2010 | 1 | 56% | 50% | 72% | 33% | 0.61(0.46–0.76) |
| Zhou, 2010 | 0.5 | 82% | 38% | 54% | 71% | 0.72 |
| 1.5 | 48% | 86% | 75% | 66% | ||
| Shin, 2008 | 0.5 | 97% | 34% | 63% | 91% | 0.86(0.82–0.91) |
| 1 | 87% | 66% | 75% | 82% | ||
| 1.4 | 78% | 83% | 84% | 77% | ||
| 1.5 | 75% | 83% | 83% | 74% | ||
| 2 | 58% | 89% | 86% | 65% | ||
| Wu, 2010 | 0.5 | 84% | 35% | 47% | 76% | 0.71(0.59–0.83) |
| 1.5 | 46% | 80% | 63% | 68% | ||
| Wang, 2012 | 0.5 | 58% | 79% | 54% | 82% | 0.77(0.71–0.84) |
| Ucar, 2013 | 0.54 | 73% | 59% | 70% | 63% | 0.66 |
| Chrysanthos, 2005 | 0.5 | 79% | 35% | 65% | 53% | NA |
| 1.5 | 33% | 83% | 75% | 45% | ||
| Liu, 2007 | 0.4 | 72% | 75% | 54% | 87% | 0.77 |
| Guzelbulut, 2011 | 0.5 | 87% | 45% | 36% | 91% | 0.78(0.72–0.84) |
| 1.5 | 38% | 91% | 60% | 81% | ||
| Lesmana, 2011 | 0.24 | 64% | 70% | 78% | 54% | 0.69(0.60–0.79) |
| Gumusay, 2011 | 0.7 | 70% | 87% | 54% | 93% | 0.82 |
| Basar, 2013 | 0.43 | 62% | 68% | 80% | 47% | 0.67(0.55–0.79) |
| Wang, 2012 | 0.5 | 53% | 86% | 86% | 56% | 0.78 |
| 1.5 | 22% | 98% | 95% | 46% | ||
| Liu, 2011 | 0.3 | 69% | 71% | 56% | 82% | 0.76(0.73–0.8) |
| Sebastiani, 2007 | 0.5 | 70% | 85% | 91% | 58% | 0.72(0.58–0.86) |
| 1.5 | 26% | 94% | 91% | 38% |
APRI, aspartate aminotransferase-to-platelet ratio index; AUROC, area under the receiver operating characteristic; PPV, positive predictive value; NPV, negative predictive value; 95%CI, 95% confidence interval.